**Table S3:** Treatment regimens of the Avatar patient derived xenograft models carrying the VEGFR2 WT and L840F genotypes.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Treatment** | **Company (catalog)** | **Administration** | **Dosis** | **Schedule** | **Period** |
| afatinib | MedChem Express (HY-10261) | oral | 20 mg/kg | 1X daily | 3 weeks\* |
| axitinib | Selleckchem (S1005) | oral | 30 mg/kg | 1X daily | 3 weeks\* |
| B20 | Merck | intraperitoneal | 5 mg/kg | 2X week | 3 weeks\* |
| bevacizumab | Genentech | intraperitoneal | 50 mg/kg | 2X week | 3 weeks\* |
| cabozantinib | MedChem Express (HY-13016) | oral | 10 mg/kg | 1X daily | 3 weeks\* |
| cabozantinib | MedChem Express (HY-13016) | oral | 30 mg/kg | 1X daily | 3 weeks\* |
| crizotinib | Selleckchem (S1068) | oral | 50 mg/kg | 1X daily | 3 weeks\* |
| MEKi | Selleckchem (S1036) | oral | 1 mg/kg | 1X daily | 3 weeks\* |
| MEKi + Cabozantinib | Selleckchem (S1036), MedChem Express (HY-13016) | oral | 1 mg/kg + 30 mg/kg | 1X daily | 3 weeks\* |
| pazopanib | MedChem Express (HY-10208) | oral | 50 mg/kg | 1X daily | 3 weeks\* |
| regorafenib | Selleckchem (S1178) | oral | 10 mg/kg | 1X daily | 3 weeks\* |
| sorafenib | Selleckchem (S7397) | oral | 60 mg/kg | 1X daily | 3 weeks\* |
| \*or until the tumors reach the humane endpoint | |  |  |  |  |